BioAdaptives Launches MyndMed Cognitive-Support Supplement After Positive Testing

BioAdaptives Inc. (OTCMKTS: BDPT) has announced the commercial launch of MyndMed, a next-generation dietary supplement designed to enhance memory, focus, and overall brain performance. The launch follows extensive testing with highly positive user feedback, and the company is scaling production and expanding distribution to meet anticipated high demand beginning in November.

MyndMed is formulated to support cognitive function across short-, mid-, and long-term pathways. The company describes it as “Mental Armor for Modern Minds,” featuring clinically studied ingredients that promote alertness, neuroplasticity, and cellular energy balance. The supplement is manufactured in the U.S. in cGMP-certified facilities and is third-party tested for purity.

The product is available nationwide at www.MyndMed.com. BioAdaptives, through its ClearMynd division, focuses on developing and launching products to advance cognitive performance, recovery, and enduring brain health.

This launch is significant as it taps into the growing market for cognitive health supplements, driven by an aging population and increasing awareness of brain health. The positive early demand suggests a strong consumer interest in science-backed cognitive support products. The company’s emphasis on clinically studied ingredients and third-party testing may help differentiate MyndMed in a crowded supplement market.

BioAdaptives positions itself as a pioneer in health and wellness products with innovative, science-driven formulations. The company’s stock trades on the OTC Markets under the symbol BDPT. For more information about the company, visit www.bioadaptives.com.

The full press release is available at https://nnw.fm/Lehwp. This announcement underscores the importance of continual innovation in the health and wellness sector, particularly in cognitive support, as consumers increasingly seek products that can help maintain mental sharpness in a fast-paced world.